Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T.

Future Oncol. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. Epub 2019 Aug 2.

2.

Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma.

Sukrithan V, Sandler J, Gucalp R, Gralla R, Halmos B.

Clin Lung Cancer. 2019 May;20(3):e242-e246. doi: 10.1016/j.cllc.2018.12.013. Epub 2018 Dec 24. No abstract available.

PMID:
30665873
3.

Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community.

Su CT, Chau V, Halmos B, Shah CD, Gucalp RA, Packer SH, Wilson K, Rapkin BD, Perez-Soler R, Cheng H.

Am J Clin Oncol. 2019 Mar;42(3):298-303. doi: 10.1097/COC.0000000000000516.

PMID:
30663997
4.

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T.

Future Oncol. 2018 Nov;14(27):2861-2874. doi: 10.2217/fon-2018-0711. Epub 2018 Oct 19.

5.

Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community.

Su CT, Bhargava A, Shah CD, Halmos B, Gucalp RA, Packer SH, Ohri N, Haramati LB, Perez-Soler R, Cheng H.

Clin Lung Cancer. 2018 Sep;19(5):e767-e773. doi: 10.1016/j.cllc.2018.05.019. Epub 2018 Jun 5.

PMID:
29937386
6.

Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Ohri N, Bodner WR, Kabarriti R, Shankar V, Cheng H, Abraham T, Halmos B, Gucalp R, Perez-Soler R, Kalnicki S, Garg M.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):709-715. doi: 10.1016/j.ijrobp.2017.10.032. Epub 2017 Oct 28.

PMID:
29249527
7.

Secondhand Smoke Exposure Among Community-Dwelling Adult Cancer Survivors in the United States: 1999-2012.

Akinboro O, Olorunfemi O, Basak P, Phillips E, Pomerantz D, Bernhardt B, Gucalp R, Jesmajian S, Ostroff JS.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1296-1305. doi: 10.1158/1055-9965.EPI-16-0777. Epub 2017 Jun 22.

8.

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.

Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R.

Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28.

9.

Evolving Concepts: Immunity in Oncology from Targets to Treatments.

Khan H, Gucalp R, Shapira I.

J Oncol. 2015;2015:847383. doi: 10.1155/2015/847383. Epub 2015 Apr 28. Review.

10.

Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.

Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C.

Lung Cancer. 2015 Jan;87(1):23-7. doi: 10.1016/j.lungcan.2014.10.016. Epub 2014 Nov 6.

PMID:
25468149
11.

Denosumab for treatment of hypercalcemia of malignancy.

Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK.

J Clin Endocrinol Metab. 2014 Sep;99(9):3144-52. doi: 10.1210/jc.2014-1001. Epub 2014 Jun 10.

12.

Gemcitabine-Induced Pseudocellulitis in a Patient With Recurrent Lymphedema: A Case Report and Review of the Current Literature.

Curtis S, Hong S, Gucalp R, Calvo M.

Am J Ther. 2016 Jan-Feb;23(1):e321-3. doi: 10.1097/MJT.0000000000000024. Review.

PMID:
24451298
13.

Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.

Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK.

J Natl Cancer Inst. 2013 Sep 18;105(18):1417-20. doi: 10.1093/jnci/djt225. Epub 2013 Aug 29.

14.

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R.

Lung Cancer. 2010 Apr;68(1):89-93. doi: 10.1016/j.lungcan.2009.05.009. Epub 2009 Jun 12.

PMID:
19524318
15.

Inferior vena cava syndrome from pancreatic adenocarcinoma: successful symptom palliation with endovascular stenting.

Akerman S, Kaubisch A, Gucalp R, Scher L, Haigentz M Jr.

J Palliat Med. 2008 Oct;11(8):1066-8. doi: 10.1089/jpm.2008.0091. No abstract available.

PMID:
18980442
16.

Hypercalcemia and gallium nitrate.

Gucalp R.

J Support Oncol. 2004 Nov-Dec;2(6):518-20. No abstract available.

PMID:
16329218
17.

Recurrent small cell lung cancer presenting as bilateral adnexal masses.

Sukumvanich P, Einstein M, Wagner B, Gucalp R, Goldberg GL.

Gynecol Oncol. 2005 Jan;96(1):232-4. Review.

PMID:
15589607
18.

Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.

Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Gucalp R, Ramphal R, Chow AW, Ho WG, Horn R, Feld R, Louie TJ, Territo MC, Blumer JL, Tack KJ.

Clin Infect Dis. 2001 Feb 1;32(3):381-90. Epub 2001 Jan 30.

PMID:
11170945
19.

Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients.

Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Kutteh LA, Gucalp R, Carlisle PS, Sparano J, Parker P, Salata RA.

Ann Oncol. 1998 Mar;9(3):307-11.

PMID:
9602265
20.

Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C.

Antimicrob Agents Chemother. 1997 Aug;41(8):1704-8.

21.

Overview by an oncologist: what are the imaging needs of the oncologist and oncological surgeon?

Gucalp R, Dutcher JP, Wiernik PH.

Semin Nucl Med. 1997 Jan;27(1):3-9. Review.

PMID:
9122721
22.

Paecilomyces sinusitis in an immunocompromised adult patient: case report and review.

Gucalp R, Carlisle P, Gialanella P, Mitsudo S, McKitrick J, Dutcher J.

Clin Infect Dis. 1996 Aug;23(2):391-3. Review.

PMID:
8842281
23.

Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patients.

Lazarus HM, Creger RJ, Gucalp R, Fox RM, Ciobanu N, Carlisle PS, Cooper BW, Jacobs MR.

Int J Antimicrob Agents. 1996 Jul;7(2):85-91.

PMID:
18611741
24.

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.

Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D.

Am J Med. 1996 Jun 24;100(6A):83S-89S.

PMID:
8678102
25.

Acute leukaemia following renal transplantation.

Subar M, Gucalp R, Benstein J, Williams G, Wiernik PH.

Med Oncol. 1996 Mar;13(1):9-13.

PMID:
8869934
26.

Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies.

Khalil A, Ciobanu N, Sparano JA, Gucalp R, Dutcher JP, Wiernik PH.

Bone Marrow Transplant. 1995 Jan;15(1):93-7.

PMID:
7742763
27.

Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.

Gucalp R, Theriault R, Gill I, Madajewicz S, Chapman R, Navari R, Ahmann F, Zelenakas K, Heffernan M, Knight RD.

Arch Intern Med. 1994 Sep 12;154(17):1935-44.

PMID:
8074597
28.

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, et al.

J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):147-53.

PMID:
8136948
29.

Introduction to bone marrow transplant symposium held at the Albert Einstein Cancer Center at Bronx, NY, USA, March 23 to 25, 1994.

Gucalp R, Sparano J, Dutcher JP, Wiernik PH.

Med Oncol. 1994;11(2):31-3. No abstract available.

PMID:
7850261
30.

Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen.

Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, Azar C, Garl S, Benson L.

Leukemia. 1993 Aug;7(8):1236-41.

PMID:
8350624
31.

Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.

Crilley P, Lazarus H, Topolsky D, Ciobanu N, Creger RJ, Fox RM, Bulova SI, Shina DC, Gucalp R, Cooper BW, et al.

Semin Oncol. 1993 Aug;20(4 Suppl 4):50-4; quiz 55.

PMID:
8342076
32.

Nosocomial infections in neutropenic cancer patients.

Carlisle PS, Gucalp R, Wiernik PH.

Infect Control Hosp Epidemiol. 1993 Jun;14(6):320-4.

PMID:
8360462
33.

Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2.

Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, et al.

J Immunother Emphasis Tumor Immunol. 1993 May 4;13(4):275-81.

PMID:
8101452
34.

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R, et al.

J Clin Oncol. 1993 Apr;11(4):661-70.

PMID:
8478661
35.

Clostridium cadaveris bacteremia in the immunocompromised host.

Gucalp R, Motyl M, Carlisle P, Dutcher J, Fuks J, Wiernik PH.

Med Pediatr Oncol. 1993;21(1):70-2. Review.

PMID:
8426578
36.

High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.

Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D, et al.

J Clin Oncol. 1992 Nov;10(11):1682-9.

PMID:
1403051
37.

Lymphoid lineage-associated features in acute myeloid leukaemia: phenotypic and genotypic correlations.

Paietta E, Van Ness B, Bennett J, Racevskis J, Gucalp R, Cassileth P, Wiernik PH.

Br J Haematol. 1992 Oct;82(2):324-31.

PMID:
1419814
38.

Cerebral infection complicating systemic aspergillosis in acute leukemia: clinical and radiographic presentation.

Sparano JA, Gucalp R, Llena JF, Moser FG, Wiernik PH.

J Neurooncol. 1992 May;13(1):91-100.

PMID:
1613541
39.

Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.

Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, et al.

J Clin Oncol. 1992 Jan;10(1):134-42.

PMID:
1727915
40.

Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation.

Gucalp R, Ciobanu N, Sparano J, Motyl M, Carlisle P, Wiernik PH.

Cancer. 1991 Oct 15;68(8):1842-4.

PMID:
1655226
41.

Monosomy 7 in multilineage and acute lymphoblastic leukaemia.

Paietta E, Gucalp R, Wiernik PH.

Br J Haematol. 1991 Oct;79(2):152-5.

PMID:
1958471
42.

Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha.

Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N, et al.

Cancer. 1991 Oct 1;68(7):1538-44.

PMID:
1893354
43.

Management of the febrile neutropenic patient with cancer.

Gucalp R.

Oncology (Williston Park). 1991 Jul;5(7):137-44, 147; discussion 148. Review.

PMID:
1837473
44.

Terminal transferase expression in acute myeloid leukaemia: biology and prognosis.

Gucalp R, Paietta E, Weinberg V, Papenhausen P, Dutcher JP, Wiernik PH.

Br J Haematol. 1991 May;78(1):48-54.

PMID:
2043481
45.

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.

Abrams JS, Rayner AA, Wiernik PH, Parkinson DR, Eisenberger M, Aronson FR, Gucalp R, Atkins MB, Hawkins MJ.

J Natl Cancer Inst. 1990 Jul 18;82(14):1202-6.

PMID:
2194036
46.
47.

Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia.

Paietta E, Andreeff M, Papenhausen P, Gucalp R, Wiernik PH.

Leukemia. 1989 Jan;3(1):76-8.

PMID:
2909810
48.

Translocation t(12;19)(q13;q13.3). A new recurrent abnormality in acute nonlymphocytic leukemia with atypical erythropoiesis.

Paietta E, Papenhausen P, Gucalp R, Wiernik PH.

Cancer Genet Cytogenet. 1988 Aug;34(1):19-23.

PMID:
3395990
49.

Cefoperazone plus tobramycin versus ticarcillin plus tobramycin in febrile granulocytopenic cancer patients.

Gucalp R, Lia S, McKitrick JC, Wiernik PH.

Am J Med. 1988 Jul 25;85(1A):31-5.

PMID:
3041816
50.

The 5q-- deletion: correlation of breakpoints with the immunophenotype of leukemic blast cells.

Paietta E, Papenhausen P, Gucalp R, Reed J, Wiernik PH.

Leukemia. 1987 Dec;1(12):822-4.

PMID:
3695588

Supplemental Content

Loading ...
Support Center